- Home
- ENGN vs ATAI Comparison
ENGN vs ATAI Comparison
Compare ENGN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- ATAI
- Stock Information
- Founded
- ENGN 1999
- ATAI 2018
- Country
- ENGN Canada
- ATAI Germany
- Employees
- ENGN N/A
- ATAI N/A
- Industry
- ENGN
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- ATAI Health Care
- Exchange
- ENGN Nasdaq
- ATAI Nasdaq
- Market Cap
- ENGN 297.7M
- ATAI 280.2M
- IPO Year
- ENGN N/A
- ATAI 2021
- Fundamental
- Price
- ENGN $5.25
- ATAI $1.51
- Analyst Decision
- ENGN Buy
- ATAI Strong Buy
- Analyst Count
- ENGN 9
- ATAI 4
- Target Price
- ENGN $25.89
- ATAI $9.00
- AVG Volume (30 Days)
- ENGN 56.3K
- ATAI 3.9M
- Earning Date
- ENGN 03-18-2025
- ATAI 03-27-2025
- Dividend Yield
- ENGN N/A
- ATAI N/A
- EPS Growth
- ENGN N/A
- ATAI N/A
- EPS
- ENGN N/A
- ATAI N/A
- Revenue
- ENGN N/A
- ATAI $331,000.00
- Revenue This Year
- ENGN N/A
- ATAI $80.07
- Revenue Next Year
- ENGN N/A
- ATAI N/A
- P/E Ratio
- ENGN N/A
- ATAI N/A
- Revenue Growth
- ENGN N/A
- ATAI N/A
- 52 Week Low
- ENGN $4.42
- ATAI $1.03
- 52 Week High
- ENGN $18.40
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- ENGN 34.69
- ATAI 39.86
- Support Level
- ENGN $5.14
- ATAI $1.44
- Resistance Level
- ENGN $5.98
- ATAI $1.87
- Average True Range (ATR)
- ENGN 0.62
- ATAI 0.19
- MACD
- ENGN -0.04
- ATAI -0.07
- Stochastic Oscillator
- ENGN 5.91
- ATAI 7.77
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.